RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors

Posted on by

The partnership focuses on combining novel antibody-drug conjugates RC88 and RC108 with a PD-1 inhibitor sintilimab for enhanced treatment outcomes YANTAI, China, July 9, 2023 /PRNewswire/ — RemeGen Co., Ltd. (“RemeGen” or “the Company”) (HKG: 9995, SHA: 688331), a fully-integrated…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.